<DOC>
	<DOCNO>NCT01024725</DOCNO>
	<brief_summary>A cohort 4000 community-dwelling adult follow evaluate effectiveness Finnish national A ( H1N1 ) v influenza vaccination campaign prevent first episode laboratory-confirmed A ( H1N1 ) v influenza . The safety vaccination severity disease follow primarily health care register . In subgroup 200 participant , humoral cellular immunogenicity vaccine study .</brief_summary>
	<brief_title>Evaluation Pandemic Vaccination Campaign</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Full legal competence ; Written inform consent obtain ; Assigned use service Tampere health centre communitydwelling ; At least 18 75 year old , inclusive ; Belongs target group A ( H1N1 ) v vaccination region pandemic vaccination campaign ; Able communicate fluently Finnish Swedish Able adhere protocol require study procedure without special burden risk , judge investigator designate . For total study cohort , specific exclusion criterion apply ; For subgroup followup immunogenicity vaccine ( immunogenicity cohort ) , exclusion criterion comprise : previous severe allergic reaction influenza vaccine know severe allergy ingredient vaccine previous severe allergic reaction egg significant immunological disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>A ( H1N1 ) v influenza</keyword>
	<keyword>vaccination</keyword>
	<keyword>pandemic</keyword>
</DOC>